Neuroimmunomodulation 2012;19:343–351

Inflammatory/Stress Feedback Dysregulation in Women with Fibromyalgia

Bote M.E. · García J.J. · Hinchado M.D. · Ortega E.
Group of Immunophysiology, Department of Physiology, Faculty of Sciences, University of Extremadura, Badajoz, Spain
email Corresponding Author


 goto top of outline Key Words

  • IL-8
  • CRP IL-18
  • Monocyte chemotactic protein-1
  • Hsp72
  • Noradrenaline
  • Cortisol
  • Neutrophils
  • Monocytes

 goto top of outline Abstract

Objective: Although one of the current hypotheses of the aetiology of fibromyalgia (FM) syndrome involves inflammatory and neuroendocrine disorders, its biophysiology still remains unclear. The purpose of the present investigation was to study the systemic inflammatory and stress responses, as well as the innate response mediated by monocytes and neutrophils in FM patients. Methods: Twenty-five women diagnosed with primary FM and 20 age-matched healthy women (control group) were enrolled in the study. Circulating ‘neuroendocrine-stress’ biomarkers (CRH, ACTH, cortisol, NA, eHsp72, serotonin and IGF-1) were evaluated by ELISA. Serum IL-8 and CRP concentrations were also determined by ELISA, and inflammatory cytokine release by monocytes [IL-1β, TNFα, IL-6, IL-10, IL-18, monocyte chemotactic protein-1 (MCP-1) and RANTES] was evaluated by the Luminex BioPlex system. The phagocytic process of neutrophils (chemotaxis, phagocytosis and microbicide capacity) was also evaluated. Results: FM patients showed an inflammatory state accompanied by an altered stress response. This is mainly manifested by high circulating levels of IL-8 and CRP (in 100% of the FM group), high circulating levels of cortisol, and increased systemic levels of NA and eHsp72. There is also increased release of inflammatory cytokines (IL-1β, TNFα, IL-6, IL-10, IL-18 and MCP-1) by monocytes, and enhanced activation of the functional capacity of neutrophils (chemotactic, phagocytic and fungicidal activities). Conclusion: An inflammatory/stress feedback dysregulation underlies FM. Whether dysregulation of the stress response is the cause of the inflammatory dysregulation or vice versa is also discussed.

Copyright © 2012 S. Karger AG, Basel

goto top of outline Introduction

The diagnostic criteria of the American College of Rheumatology (ACR) currently define fibromyalgia (FM) as the presence of widespread pain (on both the left and the right sides of the body, both above and below the waist, and obligatorily with axial skeletal pain being present) and tenderness at 11 or more of 18 specific tender point sites [1]. In general FM is associated with such symptoms as reduced physical strength, fatigue, sleep disorders and psychiatric disorders (e.g. depression). Despite this symptom-based definition, the lack of objective criteria has led to doubts about the diagnosis of the pathology and even about its existence. It has been proposed, however, that alterations in the stress and inflammatory responses could be involved, without knowing which of the two is cause and which is consequence. Indeed, the biophysiology of FM remains elusive, and treatment of the syndrome is generally empirical.

In a recent hypothesis proposed for the aetiology of FM, Van West and Maes [2] put forward the idea that inflammatory disorders accompanied by changes in the neuroendocrine-immune system might underlie the syndrome. However, in view of the variety of biophysiological aspects that seem to be implicated in the aetiology of FM, Müller et al. [3] propose that it should not be regarded as a single clinical entity but rather as a syndrome with multiple causes, and that therefore the term FM syndrome (FMS) should always be applied. They establish different subgroups of FMS, with the top of the classification hierarchy being primary or secondary FM. Whilst in secondary FM underlying diseases such as inflammatory rheumatic processes are frequently diagnosed, clinical studies of primary FM do not reveal any organic factor, meaning biochemical markers need to be identified to better characterize the disease. Primary FM is in turn subdivided into four groups [3], the first of which being that into which all the volunteer patients of the present study belonged: FM with extreme sensitivity to pain but no associated psychiatric problems [4]. Although there are conflicting results related to cytokine levels [5,6], FM might be caused by a mild inflammatory condition, since most FM patients show elevated concentrations of serum IL-8 [5,7,8], of IL-6 in the supernatants of PBMC [5], and of IL-1β, TNF-α, IL-6 and IL-10 in the supernatants of isolated monocytes [9].

One methodological problem is that many previous studies have been conducted on only small groups of patients, evaluating either inflammatory or neuroendocrine markers but not both, and comparing the results with the values expected for healthy individuals and not always with the values measured for a sex- and age-matched control group. It is important to unify the criteria for grouping FM patients in accordance with published classifications, above all for distinguishing primary from secondary FM patients since FM patients with other underlying pathologies that may contribute to triggering the syndrome can hinder the interpretation of the results if FM patients are considered as a whole. Also, patients with severe depression should be considered as a separate group [8,10].

The objective of the present study was to evaluate systemic inflammatory (CRP and IL-8) and neuroendocrine stress (CRH, ACTH, cortisol, NA, eHsp72, serotonin and IGF-1) markers and the functional capacity of isolated monocytes [release of IL-1β, TNF-α, IL-6, IL-10, IL-8, IL-18, monocyte chemotactic protein-1 (MCP-1) and RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted)] and neutrophils (phagocytic process) in a group of primary FM patients (all women belong to the Fibromyalgia Associations of Don Benito and Badajoz, Spain), comparing the results not only with the general values expected in healthy individuals, but also with those of an age-matched control group of healthy women (HW). It is perhaps remarkable that, to the best of our knowledge, this is the first investigation to evaluate the circulating concentration of eHsp72 and the release by monocytes of IL-8, IL-18, MCP-1 and RANTES, and the chemotactic and fungicidal capacity of neutrophils in women with FM.


goto top of outline Materials and Methods

goto top of outline Study Design and FM Patients

FM volunteers: 25 women between 30 and 60 years old, diagnosed with FM by a rheumatologist (according to the ACR criteria for the syndrome) were enrolled in the study. These FM patients belonged to the Fibromyalgia Associations of Don Benito, Badajoz Province, Spain, and Badajoz, Spain. They were requested to fill out a questionnaire about their lifestyle (diet, habits, etc.), medication and other previous or current concomitant illnesses. All procedures were carried out with the written consent of the subjects. Exclusion criteria consisted of neoplastic illness (diagnosed from the medical history), infection, cardiopulmonary, vascular or other internal medical conditions, or use of oral or local corticosteroids or anticytokine therapy that could influence the level of cytokines. All these FM volunteers were classified as belonging to the primary group (with no definitive organic factor triggering the syndrome) according to the classification criteria of Müller et al. [3]: Group I – FM with sensitivity to pain but no diagnosis of depression or other relevant psychiatric disorder.

Twenty HW (who had no pain disorders or infectious illness at the time of blood sampling) served as the age-matched control group (age range 28–55 years). The same exclusion criteria were applied to the control group as for the FM volunteers.

Sampling was carried out between 8.00 a.m. and 9.00 a.m. local time. Peripheral blood samples were drawn by antecubital vein puncture. The study was approved by the Ethical Committee of the University of Extremadura (Spain) according to the guidelines of the European Community Council Directives and the Declaration of Helsinki.

goto top of outline Serum and Plasma

After extraction, blood samples for serum isolation were maintained for 15–20 min at room temperature. For plasma isolation the blood was anticoagulated with citrate during the extraction. For noradrenaline (NA) determination 40 µl of a solution containing 900 mg of EGTA and 700 mg of glutathione in 100 ml of 0.1 m NaOH was added to 2 ml of each blood sample before plasma separation. All the samples were centrifuged at 700 g for 10 min and finally the serum and plasma samples were aliquoted and stored at –80°C until assay.

goto top of outline Inflammatory Cell Isolation

Blood samples were centrifuged in a density gradient (Histopaque, Sigma), obtaining a first halo containing monocytes and lymphocytes, and a second containing neutrophils. These two cell suspensions were washed in PBS. Isolated neutrophils were adjusted to 106 cells/ml in Hanks’ medium in order to evaluate their phagocytosis performing capacity (chemotactic, phagocytic and microbicidal capacities).

Monocytes were purified from the pool of mononuclear cells using the Monocyte Isolation Kit II (Miltenyi Biotec GmbH). With this method, one obtains a suspension of monocytes with purity higher than 90%, as determined by flow cytometry. They were adjusted to 106 cells/ml of medium (Iscove Medium, GIBCO) supplemented with 10% foetal bovine serum, 1% penicillin/streptomycin and 1% l-glutamine) in order to evaluate their inflammatory cytokine releasing capacity.

goto top of outline Determination of Systemic Inflammatory and Neuroendocrine Markers

The serum concentrations of IL-8 (Diaclone), CPR (Cyclex Co. Ltd.), CRH (Cusabio), serotonin (DRG), IGF-1 (DRG) and the plasma concentrations of ACTH (DRG), NA (LDN), and eHsp72 (Stressgen) were determined using commercial ELISA kits. The plasma concentration of cortisol was determined by electrochemiluminescence (Roche Elicys).

goto top of outline Determination of Inflammatory Cytokines Released by Monocytes

Monocytes were cultured for 24 h at 37°C, 5% CO2 and 100% RH in flat-bottom 48-well cell culture plates (Falcon, Becton Dickinson Labware). Cell viability was checked by the Trypan Blue Exclusion Test, finding at least 98% viable cells. Supernatants were aliquoted in Eppendorf tubes and stored at –80°C until assay. The constitutive release by monocytes of IL-1β, TNFα, IL-6, IL-10, IL-8, IL-18, MCP-1 and RANTES was evaluated using the Bio-Plex® system (Luminex, BioRad). This system uses fluorescently dyed beads, a flow cytometer and associated optics, and a high-speed digital signal processor to detect of up to 100 different types of molecules in a single well of a 96-well microplate.

goto top of outline Study of the Neutrophils’ Phagocytic Process

Chemotaxis, phagocytic and fungicidal capacities against Candida albicans, phagocytic capacity against inert particles, and oxygen-dependent microbicidal capacity (production of O2) were evaluated in neutrophils as follows.

goto top of outline Chemotaxis Assay

Neutrophil chemotaxis was evaluated in a Boyden chamber with a modification [11] of the original technique [12], using an isopore polyvinylpyrrolidone-free polycarbonate filter with a pore diameter of 3 µm (Millipore) placed between the two compartments of the chamber. n-formyl-methionyl-leucyl-phenylalanine peptide (10–8m, Sigma) diluted in PBS was used as a chemoattractant in the lower compartment of the chamber. This technique is appropriate for the quantitative evaluation of chemotaxis in isolated phagocytes [11]. Aliquots of 300 µl neutrophil suspension (106 cells/ml of Hanks’ medium) were put into the upper compartment of the Boyden chamber and allowed to migrate through the filter for 90 min at 37°C in a 5% CO2 atmosphere. After incubation, the filters were removed from the chambers, fixed and stained. The Chemotaxis Index was determined as the number of neutrophils counted at random (under phase contrast microscopy × 100) in sixteen fields of the lower face of the filter.

goto top of outline Phagocytic and Fungicidal Capacities

The neutrophils’ phagocytic and fungicidal capacities against C. albicans were evaluated ex vivo using a quantitative technique previously validated for isolated neutrophils [13,14]. Briefly, 0.5 ml of C. albicans suspension (106 cells/ml) and 50 µl of serum were added to 0.5 ml of the neutrophil suspension (106 cells/ml), followed by incubation in a thermostatic bath at 37°C for 60 min with shaking. The samples were then centrifuged at 300 g for 10 min, discarding two-thirds of the supernatant. The remainder of the supernatant was shaken and an aliquot was taken to count the number of C. albicans ingested by 100 neutrophils (Phagocytosis Index) in a Neubauer haemocytometer under phase contrast microscopy.

To evaluate the killing of phagocytosed C. albicans, a similar procedure to that used for the Phagocytosis Index was followed, but adding 1.5 ml of methylene blue (0.01%; which stains the dead C. albicans) at 50 min of incubation. The samples were then centrifuged at 300 g for 10 min, and the number of phagocytosed and dead C. albicans determined. The results are expressed as the percentage of dead C. albicans of the total phagocytosed by 100 neutrophils (Candidicide Index).

goto top of outline Phagocytosis of Inert Particles and Production of O2

Two hundred microlitres of cell suspension (106 neutrophils/ml) were incubated (37°C and 5% CO2) on culture plates for 30 min, and 20 µl of latex beads (1.09 µm, diluted to 1%; Sigma) were then added. After 30 min of incubation, the plates were washed, fixed and stained, and the number of particles ingested by 100 neutrophils was determined (Latex Bead Phagocytosis Index) under phase contrast microscopy [15].

The neutrophils’ oxygen-dependent microbicidal capacity (production of O2) was evaluated by the Nitroblue Tetrazolium (NBT) Reduction Test [15]. An aliquot of 250 µl of neutrophil suspension (106 cells/ml) was incubated for 30 min with an equal volume of NBT (Sigma, 1 mg/ml in PBS solution) in the presence of 20 µl of latex beads (1.09 mm 1% in PBS). Aliquots of neutrophil suspension incubated in the absence of latex beads were used as non-stimulated samples and a solution with the same reactants and medium without neutrophils was used as blank. In all cases, the reaction was stopped with 2.5 ml hydrochloric acid (0.5 n) after 30 min of incubation. The samples were centrifuged for 30 min at 600 g and 4°C, the supernatant discarded, and the reduced NBT (formazan) extracted from the cell pellet with 1 ml of dioxan. The tubes were then centrifuged for 30 min at 600 g, and the absorbance of the supernatant was determined in a spectrometer at 525 nm.

goto top of outline Statistical Analysis

The values are expressed as mean ± SEM. The normality of the variables was checked, followed by Student’s t test for normally distributed samples or Mann-Whitney test for nonparametric samples. The significance level was set at p < 0.05.


goto top of outline Results

goto top of outline Systemic Inflammatory and Neuroendocrine Markers

As expected, the circulating levels of IL-8 were markedly higher in patients with FM compared with the control group of HW (p < 0.001; fig. 1a). It is important to note that not only did we find a higher IL-8 concentration in the FM group as a whole with respect to the healthy control group, but also that the concentration was higher in each FM patient independently. The case was similar for CRP (p < 0.001; fig. 1b) in which we found a marked difference between the control group and the FM group, the concentration of this acute phase protein being nearly 30 times higher in the latter, with the value also being higher in each FM patient independently.

Fig. 1. Serum concentration of IL-8 (a) and CRP (b) in HW (n = 20) and in FM patients (n = 25). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. *** p < 0.001 with respect to HW (Student’s t test). 100% of FM patients presented IL-8 and CRP values higher than those of HW and the expected values according to the manufacturer (<28 pg/ml for IL-8 and <0.5 µg/ml for CRP).

Figure 2 shows the results relating to HPA axis activity. Women with FM presented lower systemic concentrations of CRH (p < 0.05) and ACTH (p < 0.05), and higher concentrations (p < 0.05) of cortisol than the age-matched control group.

Fig. 2. HPA axis activity: circulating concentration of CRH (a), ACTH (b) and cortisol (c) in HW (n = 20) and in FM patients (n = 25). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. The circulating concentration of cortisol is higher in FM patients than in HW. * p < 0.05 with respect to HW (Student’s t test).

Other stress markers such as NA (fig. 3a) and eHsp72 (fig. 3b) were also higher (p < 0.001 and p < 0.01, respectively) in FM patients. Conversely, this group presented lower serum levels of serotonin (p < 0.01; fig. 4) and of the main mediator of the anabolic effects of growth hormone (GH), the ‘insulin-related growth factor-1’ IGF-1 (p < 0.05; fig. 5).

Fig. 3. Plasma concentration of NA (a) and eHsp72 (b) in HW (n = 20) and in FM patients (n = 25). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. Circulating concentrations of NA and eHsp72 are higher in FM patients than in HW. ** p < 0.01, *** p < 0.001 with respect to HW (Student’s t test).

Fig. 4. Serum concentration of serotonin in HW (n = 20) and in FM patients (n = 25). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. Concentration of serotonin is lower in FM patients than in HW. ** p < 0.01 with respect to HW (Student’s t test).

Fig. 5. Serum concentration of IGF-1 in HW (n = 20) and in FM patients (n = 25). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. Circulating concentration of IGF-1 is lower in FM patients than in HW. * p < 0.05 with respect to HW (Student’s t test).

goto top of outline The Monocytes’ Functional Capacity

Figure 6 shows the results relating to the capacity of monocytes to release inflammatory cytokines. The monocytes from FM women released constitutively more IL-1β, TNFα, IL-6, IL-10, IL-18 and MCP-1 than those from HW, but less RANTES. No inter-group significant differences were found in the release of IL-8 (5,521 ± 2,374 pg/ml for FM vs. 4,260 ± 1,501 pg/ml for HW).

Fig. 6. IL-1β, TNF-α, IL-6, IL-10 (left scale), IL-18, MCP-1 and RANTES (right scale) release by monocytes of HW (n = 8) and FM patients (n = 17). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. The monocytes from FM patients released more IL-1β, TNFα, IL-6, IL-10, IL-18 and MCP-1, and less RANTES, than those from HW. * p < 0.05 compared with HW (Mann-Whitney test). Determinations were made using the BioPlex System (LUMINEX).

goto top of outline The Neutrophils’ Functional Capacity

The chemotaxis (fig. 7a), phagocytosis against C. albicans (fig. 7b) and fungicidal (fig. 7c) capacities of neutrophils were greater in the FM patients than in the healthy control group, but the latex bead phagocytosis index was lower (fig. 7d), and no differences were found in the production of O2 (fig. 7e).

Fig. 7. Functional capacity of neutrophils: chemotactic (a), phagocytic (b) and fungicidal (c) capacities, phagocytosis of latex beads (d), and O2 production (e) in HW (n = 7) and FM patients (n = 18). Columns represent the mean ± SEM of independent experiments performed in duplicate in each HW volunteer and each FM patient. The neutrophils from FM patients presented higher chemotactic, phagocytic and fungicidal capacities, and lower latex bead phagocytosis than those from HW. * p < 0.05, *** p < 0.001 with respect to HW (Student’s t test).


goto top of outline Discussion

goto top of outline Systemic Inflammatory and Neuroendocrine Markers

To the best of our knowledge, the present work represents the first complete study of both the functional capacity of inflammatory cells and the systemic inflammatory and neuroendocrine status of a single group of women diagnosed with primary FM, compared with a control group of age-matched healthy women. IL-8 can promote sympathetic pain [16] and, therefore, must be considered as playing a potential role in FM [5]. As expected, we found elevated serum concentrations of IL-8 in the patients with FM compared to the control group. Most of the few previous studies also report increased serum levels of IL-8 in FM patients [5,6,8,17,18] irrespective of differences in the aetiology of the illness [8]. In the present study, it is important to note that each FM patient had a higher concentration of IL-8 than not only the expected value in healthy people, but also the control group of age-matched HW. Taking this into account, the absence of elevated levels of IL-8 could contribute as an exclusion criterion for FM diagnosis. With respect to CRP (a generic inflammatory marker), the results confirm both a previous report that FM patients present levels above the expected normal range in healthy people (<0.5 µg/ml) [17], and our own findings in an earlier study on a small group of FM patients [8]. In particular, the present results show the FM patients to have higher circulating concentrations of CRP than the age-matched control group of HW (also below 0.5 µg/ml), and that this held for each of the FM patients considered separately.

The results relating to the HPA axis showed a higher circulating concentration of cortisol paralleled by low ACTH and CRH levels in the FM patients. This corresponds to a disrupted HPA axis, as has been previously reported in studies evaluating circadian variations of ACTH and cortisol in these patients [19]. Nevertheless, a limitation of our study may be that we measured cortisol and ACTH only once. This is because another study assessing the feedback sensitivity of the HPA axis in FM patients by conducting low-dose dexamethason suppression tests revealed normal feedback sensitivity in FM patients [20]. In any case, elevated circulating cortisol levels together with the increased systemic levels of NA denote a higher stress response in patients with FM, probably due to dysregulation of the inflammatory and stress feedback mechanisms. The mild chronic increase in cortisol found in FM patients, with a chronic low-grade inflammatory status, indicates that the HPA axis failed to control the increase of pro-inflammatory cytokines.

Hsp72 plays an important role in physiology and human health. Under normal physiological conditions, Hsp72 is expressed at low levels. However, a wide variety of pathological stressful stimuli can induce a marked increase in its intracellular synthesis [21] and extracellular release [22,23]. Inflammation also results in the release of eHsp72 [24] and high circulating levels of eHsp72 may reflect a ‘chronic low-grade inflammatory status’. To the best of our knowledge, this is the first time that an elevated circulating concentration of eHsp72 has been reported in FM patients. NA can act as a ‘stress signal’ for the release of eHsp72 [25]. Thus, increased circulating levels of NA and eHps72, together with cortisol, CRP and IL-8 reflect an alteration in the inflammatory and stress feedback mechanisms in FM.

In addition, circulating levels of serotonin are related to pain in FM patients [26,27]. Indeed, one of the pharmacological treatments currently used in FMS is a serotonin re-uptake inhibitor [28]. Coherent with reports in the literature [28], we found the circulating serotonin levels to be lower in the FM group than in the healthy control group, confirming the role serotonin plays in the neuroendocrine disorders associated with FMS. Treatment of GH deficiency in adults has also been reported to reduce pain and improve quality of life [29]. The main mediator of the effects of GH is somatomedin C, also called ‘insulin-related growth factor-1’ (IGF-1). This has a half-life of approximately 21 h and no diurnal variations, so that its plasma levels are considered to reflect an integration of the pulses of GH secretion during the previous 48 h. For these reasons, studies of FM patients have primarily evaluated IGF-1. Although it has been reported that there are no differences in the systemic levels of IGF-1 connected with FM [30], most investigations report evidence for deficient GH function in FM patients as reflected in the serum levels of IGF-1, and that this could be secondary to some dysfunction in the hypothalamic-hypophyseal-GH axis [31,32]. Our results are coherent with the latter and the majority of studies, given that we found a significantly lower concentration of IGF-1 in FM patients compared with the control group, thus confirming that IGF-1 is involved in some alterations associated with this syndrome. Nevertheless, since GH deficiency is not always associated with FM, it has been suggested that it is an epiphenomenon in this pathology, although treatable and with clinical relevance, since GH appears to improve symptoms of FM including pain, and hence also the patient’s quality of life [32].

goto top of outline Functional Capacity of Monocytes

During a local inflammatory response, TNFα, IL-1β and IL-6 are the main cytokines released by monocytes, together with the anti-inflammatory cytokine IL-10, which is released later. The monocytes from FM patients released more IL-1β, TNFα, IL-6, IL-10 (as well as IL-18 and MCP-1, but less RANTES) than those from the control group, as determined using an innovative sensitive technique (Bio-Plex system, Luminex). This confirms our previous results for IL-1β, TNFα, IL-6 and IL-10 determined by ELISA in a small number of FM patients [9].To the best of our knowledge, there have been no previous publications on the role of IL-18 and RANTES in FMS. IL-18 was initially described as the induction factor of IFN-γ. It is a pro-inflammatory cytokine that contributes to the organism’s systemic and local defences, and thus has been proposed as being one of the main pro-inflammatory cytokines involved in inflammatory diseases [33,34]. MCP-1 is a cytokine secreted by antigen-presenting cells. It participates in the recruitment of neutrophils (and monocytes), and is required for their early accumulation at points of inflammation [35]. The increased release of MCP-1 in the FM group may explain, at least in part, the reduced local release of RANTES by the monocytes of the women in that group, since it has been shown that treating macrophages with MCP-rm-1 selectively suppresses RANTES expression [35]. Although previous results concerning the systemic levels of MCP-1 in this syndrome have been controversial [36,37], it seems clear that the release of this cytokine by monocytes is altered in FMS. The results presented here confirm the hypothesis of a dysregulated inflammatory response in FMS that involves monocytes, however, no significant differences were found between women with FM and HW in the release by monocytes of IL-8, which seems to indicate that, surprisingly, monocytes are not the main source of the elevated systemic concentration of IL-8 in women with FM. One might speculate, therefore, that the origin could be endothelial cells. Further investigation in this line may shed some light on this question.

goto top of outline Functional Capacity of Neutrophils

The existence of sexual dimorphism in the immune response in humans, particularly in the innate and inflammatory response, is well known. Thus, the level of neutrophil activity is higher in women than men, with elevated circulating concentrations of IL-8, cortisol, NA and eHsp72 seeming to be involved. While this can give women increased resistance to infection compared to men, this enhanced ‘inflammatory status’ can also contribute to a greater incidence of inflammatory diseases [38]. In the evaluation of the neutrophils’ phagocytic process those from FM patients showed a greater chemotactic activity than those from HW. The FM patients’ elevated circulating levels of IL-8 and greater release of IL-18 and MCP-1 by monocytes could contribute to this phenomenon. FM patients are more prone to C. albicans infections than HW [39], which seems consistent with the increased phagocytic and microbicidal capacities against C. albicans found in the neutrophils from our FM patients. This greater phagocytic and fungicidal capacity (together with a greater chemotactic capacity) of neutrophils could be mediated by the raised circulating concentration of NA and eHsp72 in the FM patients, since it has been reported that increased systemic levels of NA and eHsp72 mediate the stimulation of chemotaxis, phagocytosis and the fungicidal activities of neutrophils [22,40,41,42]. However, the FM group’s decreased latex bead phagocytic capacity (a less specific form of phagocytosis because it is not mediated by pre-opsonization through antibodies) is suggestive of an immunosuppression mediated by the less specific innate immune response carried out by neutrophils. No differences were found in O2 production, so it seems that FM patients have no altered oxygen-dependent microbicidal capacity, especially considering that neutrophils from FM patients are reported as presenting elevated spontaneous H2O2 production [43].


goto top of outline Conclusion

The present study has confirmed in a group of 25 primary FM patients (compared with a group of age-matched HW) that this syndrome can be categorized as an inflammatory and stress-related disease. This was mainly manifested in raised circulating levels of IL-8 and CRP (in 100% of the FM volunteers), high circulating levels of cortisol, and increased systemic levels of NA and eHsp72. There was also an increased release of pro-inflammatory cytokines by monocytes, and increased activation of the neutrophils’ functional capacity.


goto top of outline Acknowledgments

This work was supported by MICIN-FEDER (DEP2009-10041), Junta de Extremadura-FEDER (PRI09A003, GR10020, and PRE07045), and FundeSalud (PRIS10019). We also thank the Fibromyalgia Associations of Don Benito and Badajoz, Spain, for their invaluable collaboration. We would like to thank Dr. Robert Chatwin for language revision.

 goto top of outline References
  1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al.: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–172.
  2. Van West D, Maes M: Neuroendocrine and immune aspects of fibromyalgia. BioDrugs 2001;15:521–531.
  3. Müller W, Schneider EM, Stratz T: The classification of fibromyalgia syndrome. Rheumatol Int 2007;27:1005–1010.
  4. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian TX, Gracely RH, Clauw DJ: Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003;48:2916–2922.
  5. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumathology 2001;40:743–749.
  6. Gür A, Karakoç M, Nas K, Cevik R, Denli A, Saraç J: Cytokines and depression in cases with fibromylagia. J Rheumatol 2002;29:358–361.

    External Resources

  7. Wang H, Moser M, Schiltenwolf M, Buchner M: Circulating cytokine levels compared to pain in patients with fibromyalgia: a prospective longitudinal study over 6 months. J Rheumatol 2008;35:1366–1370.
  8. Ortega E, García JJ, Bote ME, Martín-Cordero L, Escalante Y, Saavedra JM, Northoff H, Giraldo E: Exercise in fibromialgia and related inflammatory disorders: known effects and unknown chances. Exerc Immunol Rev 2009;15:42–65.
  9. Ortega E, Bote E, Giraldo E, García JJ: Aquatic exercise improves the monocyte pro- and anti-inflammatory cytokine production balance in fibromyalgia patients. Scand J Med Sci Sports 2012;22:104–112.
  10. Ortega E: Why exercise can improve the symptoms of fibromyalgia? (in Spanish.) Med Clin 2011;137:405–407.
  11. Ortega E, Forner MA, Barriga C: Exercise-induced stimulation of murine macrophage chemotaxis: role of corticosterone and prolactin as mediators. J Physiol 1997;498:729–734.
  12. Boyden S: The chemotaxis effect of mixtures of antibody and antigen on polymorphonuclear leukocyte. J Exp Med 1962;115:453–456.
  13. Ortega E, Collazos ME, Maynar M, Barriga C: Stimulation of the phagocytic function of neutrophils in sedentary men alters acute moderate exercise. Eur J Appl Physiol Occup Physiol 1993;66:60–64.
  14. Giraldo E, Martín-Cordero L, García JJ, Gerhmann M, Multhoff G, Ortega E: Exercise-induced extracellular 72 kDa heat shock protein (Hsp72) stimulates neutrophil phagocytic and fungicidal capacities via TLR-2. Eur J Appl Physiol 2010;108:217–225.
  15. García JJ, Bote E, Hinchado MD, Ortega E: A single session of intense exercise improves the inflammatory response in healthy sedentary women. Physiol Biochem 2011;67:87–94.
  16. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991;104:765–767.
  17. Bazzichi L, Rossi A, Massimetti G, Giannaccini G, Giuliano T, De Feo F, Ciapparelli A, Dell’Osso L, Bombardieri S: Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25:225–230.
  18. Gür A, Oktayoglu P: Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008;12:175–181.

    External Resources

  19. Crofford LJ, Young EA, Engleberg NC, Korszum A, Brucksch CB, McClure LA, Brown MB, Demitrack MA: Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004;18:314–325.
  20. Geiss A, Rohleder N, Anton F: Evidence for an association between an enhanced reactivity of interleukin-6 and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 2012;37:671–684.
  21. Lindquist S, Craig EA: The heat-shock proteins. Annu Rev Genet 1988;22:631–677.
  22. Ortega E, Hinchado MD, Martín-Cordero L, Asea A: The effect of stress-inducible extracllular Hsp72 on human neutrophil chemotaxis: a role during acute intense exercise. Stress 2009;12:240–249.
  23. Fleshner M, Campisi J, Amiri L, Diamond DM: Cat exposure induces both intra- and extracellular Hsp72: the role of adrenal hormones. Psychoneuroendocrinology 2004;29:1142–1152.
  24. Campisi J, Leem TM, Fleshner M: Stress-induced extracellular Hsp72 is a functionally significant danger signal to the immune system. Cell Stress Chaperones 2003;8:272–286.
  25. Giraldo E, Multhoff G, Ortega E: Noradrenaline increases the expression and release of Hsp72 by human neutrophils. Brain Behav Immun 2010;24:672–677.
  26. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J: Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24:555–559.
  27. Ernberg M, Lundeberg T, Kopp S: Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia. Pain 2003;101:275–282.
  28. Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, Sarzi-Puttini: Pharmacological treatment of fibromyalgia. Clin Exp Rheumatol 2010;28:110–116.
  29. Bennett RM, Clark SC, Walczyk J: A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227–231.
  30. McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK: Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 2003;30:809–814.
  31. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM: Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997;24:1384–1389.
  32. Cuatrecasas G, Riudavets C, Güell MA, Nadal A: Growth hormone as concomitant treatment in severe fibromialgia associated with low IGF-1 serum levels: a pilot study. BMC Musculoskelet Disord 2007;8:119.

    External Resources

  33. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, Mühl H, Yoon DY, Reznikov LL, Kim SH, Rubinstein M: Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 1998;63:658–664.
  34. Kohno K, Kurimoto M: Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998;86:11–15.
  35. Ferreira AM, Rollins BJ, Faunce DE, Burns AL, Zhu X, Dipietro LA: The effect of MCP-1 depletion on chemokine and chemokine-related gene expression: evidence for a complex network in acute inflammation. Cytokine 2005;30:64–71.
  36. Zhang Z, Cherryholmes G, Mao A, Marek C, Longmate J, Kalos M, Amand, RP, Shively JE: High plasma levels of MPC-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med 2008;233:1171–1180.
  37. Blanco I, Janciauskiene S, Nita I, Fernández-Bustillo E, Cárcaba V, Gallo C, Álvarez-Rico M, de Serres F, Béridze N: Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), and vascular endotelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia. Clin Rheumatol 2010;29:189–197.

    External Resources

  38. Giraldo E, Hinchado MD, García JJ, Ortega E: Influence of gender and oral contraceptives intake on innate and inflammatory response: role of neuroendocrine factors. Mol Cell Biochem 2008;313:147–153.
  39. Garrison RL, Breeding PC: A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Med Hypotheses 2003;61:182–189.
  40. Ortega E, Giraldo E, Hinchado MD, Martinez M, Ibáñez S, Cidoncha A, Collazos ME, García JJ: Role of Hsp72 and norepinephine in the moderate exercise-induced stimulation of neutrophils’ microbicide capacity. Eur J Appl Physiol 2006;98:250–255.
  41. Ortega E, Giraldo E, Hinchado MD, Marín L, García JJ, De la Fuente M: Neuroinmmunomodulation during exercise: role of catecholamines as ‘stress mediator’ and/or ‘danger signal’ for the innate immune response. Neuroinmmunomodulation 2007;98:250–255.
  42. Ortega E, Giraldo E, Hinchado MD, Martín-Cordero L, García JJ: 72 kDa extracellular heat shock protein (eHsp72), norepinephrine (NE), and the innate immune response following moderate exercise; in Asea A, Pedersen BK (eds): Heat Shock Proteins and Whole Body Physiology. New York, Springer, 2010, pp 329–350.
  43. Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M: Anandamide and neutrophils function in patients with fibromyalgia. Psychoneuroendocrinology 2008;33:676–685.

 goto top of outline Author Contacts

Dr. Mª Elena Bote
Group of Immunophysiology, Department of Physiology
Faculty of Sciences, University of Extremadura
Avda. De Elvas s/n, ES–06071 Badajoz (Spain)
Tel. +34 924 289 388, E-Mail

 goto top of outline Article Information

Received: May 9, 2012
Accepted after revision: June 29, 2012
Published online: September 12, 2012
Number of Print Pages : 9
Number of Figures : 7, Number of Tables : 0, Number of References : 43

 goto top of outline Publication Details


Vol. 19, No. 6, Year 2012 (Cover Date: October 2012)

Journal Editor: Savino W. (Rio de Janeiro)
ISSN: 1021-7401 (Print), eISSN: 1423-0216 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.